The effects of metformin on weight loss in women with gestational diabetes: a pilot randomized, placebo-controlled trial

• Published in: American journal of obstetrics and gynecology Vol. 212; no. 3; pp. 389.e1 - 389.e9
• Main Authors: Refuerzo, Jerrie S., MD, Viteri, Oscar A., MD, Hutchinson, Maria, MS, Pedroza, Claudia, PhD, Blackwell, Sean C., MD, Tyson, Jon E., MD, MPH, Ramin, Susan M., MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2015
• Subjects: Adolescent; Adult; Diabetes, Gestational - drug therapy; Drug Administration Schedule; Female; Follow-Up Studies; gestational diabetes; Humans; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Intention to Treat Analysis; Medication Adherence - statistics & numerical data; metformin; Metformin - pharmacology; Metformin - therapeutic use; Middle Aged; Obstetrics and Gynecology; Patient Satisfaction - statistics & numerical data; Pilot Projects; Postnatal Care - methods; Pregnancy; Treatment Outcome; weight loss; Weight Loss - drug effects; Young Adult; weight loss; metformin; gestational diabetes
• ISSN: 0002-9378; 1097-6868
• DOI: 10.1016/j.ajog.2014.12.019

Objective We sought to compare weight loss in the first 6 weeks postpartum among women with gestational diabetes mellitus (GDM) treated with metformin or placebo, a promising therapy to reduce later risk of progression to diabetes mellitus. Study Design We conducted a pilot, randomized trial of metformin vs placebo in postpartum women with GDM. Women with pre-GDM, unable to tolerate metformin, resumed on insulin or oral hypoglycemic agent, delivered <34 weeks’ gestation, or with a body mass index <20 kg/m2 were excluded. Women were randomized to either metformin 850 mg daily for 7 days, then metformin 850 mg twice a day for the next 5 weeks or placebo prescribed in a similar frequency. The subject, health care provider, and research staff were blinded to the treatment. The primary outcome was weight change from delivery to 6 weeks postpartum. Secondary outcomes included the percentage of women achieving their self-reported prepregnancy weight, reported medication adherence, adverse effects, and satisfaction. Differences in weight change between groups were determined by Wilcoxon rank sum test and in achieving prepregnancy weight by χ2 test. Results Of 114 women randomized, 79 (69.3%) completed the 6 weeks; 36 (45.6%) were randomized to metformin and 43 (54.4%) to placebo. Metformin and placebo groups were similar in median weight loss (6.3 kg [range, –0.3 to 19.8] vs 6.5 kg [range, –0.3 to 12.1], P  = .988) and percentage of women achieving reported prepregnancy weight (41.7 vs 37.2%, P  = .69). Self-reported adherence in taking >50% of medication was 75% at 3 weeks and 97% at 6 weeks. Nausea, diarrhea, and hypoglycemia were reported in approximately 11-17% of women and 56-63% reported dissatisfaction with the medication. Conclusion Women with GDM lost approximately 6 kg by 6 weeks' postpartum. This was similar in both groups and resulted in <50% of women achieving their prepregnancy weight. Although the reported adherence and satisfaction with the medication was high, adverse effects were reported with nearly 1 in 5 women including nausea, diarrhea, and hypoglycemia. Contrary to expectation, we found no evidence of benefit from metformin. However, longer treatment periods and larger studies with minimal attrition may be warranted.